There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion
molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc …

The development of recombinant therapeutic proteins has been a major revolution in
modern medicine. Therapeutic-based monoclonal antibodies (mAbs) are growing rapidly …

Major advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have
created revolutionary drug delivery systems in cancer over the past decade. While these …

Monoclonal antibodies (mAbs) are currently the largest and most dominant class of
therapeutic proteins. Inter-individual variability has been observed for several mAbs; …

There is increasing interest in the clinical implications and immunology of trogocytosis, a
process in which the receptors on acceptor cells remove and internalize cognate ligands …

Introduction: Dose design for pediatric trials with monoclonal antibodies (mAbs) is often
extrapolated from the adult dose according to weight, age, or body surface area. While these …

Over the past 25 years, antibodies have emerged as extraordinarily promising vectors for the
delivery of radionuclides to tumors for nuclear imaging. While radioimmunoconjugates often …

Many chronic inflammatory diseases are treated by administration of “biological” therapies in
terms of fully human and humanized monoclonal antibodies or Fc fusion proteins. These …

Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA
approvals in the last two years and a projected market value of over $4 billion by 2024 …

Antibody-drug conjugates (ADCs) are ushering in the next era of targeted therapy against
cancer. An ADC for cancer therapy consists of a potent cytotoxic payload that is attached to a …